 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...910111213141516171819...266267» |
- | Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Trial initiation date, Checkpoint inhibition, IO biomarker: Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 2, 2024
P1, N=18, Not yet recruiting, Sponsor: Emory University
Initiation date: Jun 2024 --> Sep 2024
- || Bavencio (avelumab) / EMD Serono, Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Clinical, P2 data, Journal: A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors. (Pubmed Central) - Jul 2, 2024
P2
SBRT and pembrolizumab with or without IT avelumab/ipilimumab and IT myDC in oligometastatic patients are safe and feasible with a clinically meaningful tumor response rate. However, the study failed to reach its primary endpoint.
- ||| Journal, Adverse events, Checkpoint inhibition: Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database. (Pubmed Central) - Jul 2, 2024
This study provides a comprehensive understanding of ICIs-induced ITP. Clinicians should pay attention to this potentially fatal adverse reaction.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Vitreous Haemorrhage and Retinal Neovascularization Secondary to Peripheral Retinal Ischemia as the Presenting Sign of a Disseminated Melanoma. (Pubmed Central) - Jul 1, 2024
Clinicians should pay attention to this potentially fatal adverse reaction. Immune checkpoint inhibitor therapy with ipilimumab/nivolumab was initiated.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Dual immunotherapy alternating with anti-PD-1 antibody plus liposomal doxorubicin show good efficacy in prostate epithelioid hemangioendothelioma: a case report. (Pubmed Central) - Jul 1, 2024
Our report suggests that dual immunotherapy alternating with anti-PD-1antibody plus doxorubicin may be a potential treatment modality for epithelioid hemangioendothelioma. However, larger sample studies are necessary to ascertain the effectiveness of this treatment strategy and it is essential to continue monitoring this patient to sustain progression-free survival and overall survival.
- | Avastin (bevacizumab) / Roche
New P2 trial, Checkpoint inhibition: Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT (clinicaltrials.gov) - Jun 30, 2024
P2, N=90, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- || Clinical, Retrospective data, Review, Journal, Checkpoint inhibition, Metastases: Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis. (Pubmed Central) - Jun 27, 2024
The safety ranking of treatments based on ICIs is significantly influenced by specific irAEs. These irAEs, which vary in type and severity, play a crucial role in determining the overall safety profile of each ICI regimen.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Review, Journal, Metastases, Immune cell: Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage. (Pubmed Central) - Jun 27, 2024
Ongoing clinical trials are actively exploring the combination of checkpoint inhibitory therapies, aiming to decipher their synergistic effects and efficacy against diverse cancer types. This review discusses the mechanisms, adverse effects, and various clinical trials involving nivolumab and ipilimumab across different cancers, emphasizing their transformative impact on cancer treatment.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
P2 data, Journal, Metastases: Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab+Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC. (Pubmed Central) - Jun 27, 2024
P2
However, only symptomatic patients would have had to discontinue treatment due to amylase or lipase laboratory values. In conclusion, a reduced frequency of laboratory testing appears to be acceptable in asymptomatic patients with metastatic renal cell carcinoma treated with nivolumab or nivolumab+ipilimumab.
- || Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
P1 data, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. (Pubmed Central) - Jun 26, 2024
P1
Exploratory analyses revealed that changes in myeloid cells may contribute to responses; however, no correlation was noted between changes in CD8:FoxP3 ratio, PD-L1 status and tumor mutational burden and response. These findings support further investigation of this treatment in a phase II trial.
- | Yervoy (ipilimumab) / BMS
Journal: Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice. (Pubmed Central) - Jun 26, 2024
Forty-six developed significant diarrhea (19%) and thirty-four (74.4%) had a rapid resolution of diarrhea following glucocorticosteroid and infliximab treatment...After the control of diarrhea, most patients were able to continue their planned immunotherapy. Further testing in 11/46 patients with unresponsive diarrhea revealed additional diagnoses, allowing their treatment to be adjusted.
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
Journal, Tumor mutational burden, PD(L)-1 Biomarker: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. (Pubmed Central) - Jun 26, 2024
A repeat biopsy following the development of lurbinectedin resistance showed a new actionable ERBB2 alteration without significant change in the tumor mutation burden (six mutations/Mb). The present report suggests that lurbinectedin may be active and should be further explored in SCBC harboring TP53 mutations and amplifications in E2F3 and MYC family complexes.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden. (Pubmed Central) - Jun 25, 2024
To the best of our knowledge, this is the first successful use of a long-term two-drug immunotherapy (48 weeks) in a patient with metastatic adrenocortical cancer and high mutational burden. Ipilimumab and nivolumab should be considered as a new therapy option in this patient group.
- | Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2024
P1/2, N=100, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Ipilimumab and nivolumab should be considered as a new therapy option in this patient group. Trial completion date: Oct 2025 --> Oct 2035 | Trial primary completion date: Oct 2024 --> Oct 2029
- | Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Trial completion date, Checkpoint inhibition, Metastases: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2024
P2/3, N=200, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Trial completion date: Oct 2025 --> Oct 2035 | Trial primary completion date: Oct 2024 --> Oct 2029 Trial completion date: Nov 2033 --> Nov 2036
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical Trial,Phase II, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma. (Pubmed Central) - Jun 24, 2024
P2
Trial completion date: Nov 2033 --> Nov 2036 Circulating levels of immune-related proteins like FASLG and Gal-1 might be used to predict the efficacy of checkpoint inhibitors in patients with metastatic PDAC.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition: Severe Multifocal Placoid Chorioretinitis Associated with Immune Checkpoint Inhibitor Therapy. (Pubmed Central) - Jun 24, 2024
Extensive multifocal placoid chorioretinitis may occur in patients undergoing immune checkpoint inhibitor therapy. Some patients with immune checkpoint inhibitor-related uveitis may successfully resume immune checkpoint inhibitor therapy under close collaboration with the treating oncologist.
- ||| iSCIB1+ / Scancell, SCIB1 / Scancell
Enrollment change: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) (clinicaltrials.gov) - Jun 23, 2024
P2, N=130, Recruiting, Sponsor: Scancell Ltd
Some patients with immune checkpoint inhibitor-related uveitis may successfully resume immune checkpoint inhibitor therapy under close collaboration with the treating oncologist. N=87 --> 130
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Longitudinal Tumor Microenvironment Analysis In Dual Checkpoint Inhibitor Blockade Using Ipilimumab/Nivolumab In Patients With Advanced Stage Small Cell Lung Cancer () - Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_84;
P2
Immunotherapy induced changesin TIL number and composition are associated with clinical activity. We identified multiple novel genetic and transcriptional changes in week 4 and progression samples which may be implicated in immunotherapy resistance.
- | Kimmtrak (tebentafusp-tebn) / Immunocore
Journal: Tebentafusp (Kimmtrak) for uveal melanoma. (Pubmed Central) - Jun 21, 2024
We identified multiple novel genetic and transcriptional changes in week 4 and progression samples which may be implicated in immunotherapy resistance. No abstract available
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: CA209-8H3: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (clinicaltrials.gov) - Jun 21, 2024
P2, N=30, Active, not recruiting, Sponsor: Providence Health & Services
No abstract available Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Aug 2024
- || sotigalimab (PYX-107) / Pyxis Oncology
Enrollment closed: A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Na (clinicaltrials.gov) - Jun 21, 2024
P1, N=26, Active, not recruiting, Sponsor: Yale University
Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Aug 2024 Recruiting --> Active, not recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical, Journal, Combination therapy, FDG PET: Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. (Pubmed Central) - Jun 20, 2024
Recruiting --> Active, not recruiting For unresectable MPM patient examinations, FDG-PET and CT provide accurate findings for evaluating tumor response and also prognosis prediction following first-line nivolumab plus ipilimumab immunotherapy (approximately three cycles).
- || VAC85135 / J&J
Enrollment closed, Enrollment change: A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms (clinicaltrials.gov) - Jun 19, 2024
P1, N=14, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
For unresectable MPM patient examinations, FDG-PET and CT provide accurate findings for evaluating tumor response and also prognosis prediction following first-line nivolumab plus ipilimumab immunotherapy (approximately three cycles). Recruiting --> Active, not recruiting | N=60 --> 14
- || Review, Journal, Metastases: Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. (Pubmed Central) - Jun 19, 2024
This review highlights the efficacy of multikinase inhibitors and immune checkpoint inhibitors in monotherapy and combination therapy through the analysis of phase II, and III clinical trials, targeting the key molecular pathways involved in cellular signaling and immune response for the prospective treatment of advanced and unresectable HCC and discusses the upcoming combinations of immune checkpoint inhibitors-tyrosine kinase inhibitors and immune checkpoint inhibitors-vascular endothelial growth factor inhibitors. Finally, the hidden challenges with pharmacological therapy for HCC, feasible solutions for the future, and implications of possible presumptions to develop drugs for HCC treatment are reported.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Metastases: Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment-The Experience of Ion Chiricu?? Oncology Institute. (Pubmed Central) - Jun 19, 2024
Efficacy results using different immunotherapy combination strategies were promising and not significantly different between protocols at 2 years. Real-world efficacy and long-term results in our series were in line with those reported in the corresponding registration trials.
- | Journal: Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma. (Pubmed Central) - Jun 19, 2024
All patients received ICPI including atezolizumab/bevacizumab (N = 4), nivolumab/ipilimumab (N = 1), and nivolumab as monotherapy (N = 1)...All patients received tacrolimus plus mycophenolate as immunosuppressant (IS) therapy post-OLT and one patient received prednisone as additional IS...In addition, this study illustrated the importance of timing for the administration of ICPI before OLT. Given the lack of conclusive evidence in this therapeutic area, we believe that our study lays the groundwork for prospective trials to further examine the impact of ICPI prior to OLT.
- | Journal, Metastases: Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. (Pubmed Central) - Jun 19, 2024
A substantial proportion of patients with metastatic renal cell carcinoma utilize dietary modification and supplements as an adjunct to antineoplastic therapy. Considering the widespread adoption of these practices and the reported effects on cancer treatment, it is crucial for healthcare providers to engage in discussions with patients regarding supplement use.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition: A rare case of immune checkpoint inhibitor-induced meningoradiculitis with vocal cord diplegia. (Pubmed Central) - Jun 18, 2024
Considering the widespread adoption of these practices and the reported effects on cancer treatment, it is crucial for healthcare providers to engage in discussions with patients regarding supplement use. No abstract available
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Observational data, Retrospective data, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study. (Pubmed Central) - Jun 17, 2024
Given that pivotal clinical trials of ipilimumab-nivolumab did not formally compare ipilimumab-nivolumab with nivolumab monotherapy, this work adds context to differences in outcomes when these agents are used. These results may inform treatment selection, and aid in counseling of patients treated with first-line ICI therapy in routine clinical practice settings.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial termination: Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (clinicaltrials.gov) - Jun 17, 2024
P1/2, N=35, Terminated, Sponsor: Hackensack Meridian Health
These results may inform treatment selection, and aid in counseling of patients treated with first-line ICI therapy in routine clinical practice settings. Active, not recruiting --> Terminated; Lack of Accrual
- | CIML NK - Dana / Farber Cancer Institute
Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Jun 16, 2024
P1, N=25, Recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Terminated; Lack of Accrual Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Neoadjuvant ipilimumab-nivolumab superior to adjuvant nivolumab. (Pubmed Central) - Jun 15, 2024
Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 No abstract available
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
P2 data, Journal, Metastases: Nivolumab With or Without Ipilimumab Combined with Stereotactic Body Radiotherapy in patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study. (Pubmed Central) - Jun 14, 2024
No abstract available Combining SBRT, nivolumab and ipilimumab is well tolerated, feasible, and shows response in a subgroup of patients with mBTC.
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date: RATIO: Rational Approach To Immuno-Oncology (clinicaltrials.gov) - Jun 14, 2024
P=N/A, N=35, Completed, Sponsor: AHS Cancer Control Alberta
Combining SBRT, nivolumab and ipilimumab is well tolerated, feasible, and shows response in a subgroup of patients with mBTC. Unknown status --> Completed | Trial completion date: Dec 2021 --> Sep 2023
- ||| tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (clinicaltrials.gov) - Jun 14, 2024
P2, N=60, Recruiting, Sponsor: The Netherlands Cancer Institute
Unknown status --> Completed | Trial completion date: Dec 2021 --> Sep 2023 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition: Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report. (Pubmed Central) - Jun 12, 2024
This case underscores the significance of recognizing and addressing the "Terrible Triad" of IRAEs in patients receiving ICIs. Healthcare providers should maintain a high index of suspicion for overlapping toxicities and promptly initiate appropriate interventions.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment. (Pubmed Central) - Jun 11, 2024
This represents the first report of pulmonary TB that developed during nivolumab and ipilimumab treatment, and recurred 2 months after completing anti-TB treatment. Physicians should be mindful of the potential for TB recurrence following the use of ICIs, particularly in patients showing positive results from IGRA.
- | CD25hi Treg depleted DLI - Dana / Farber Cancer Institute
Enrollment closed, Trial completion date: A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (clinicaltrials.gov) - Jun 10, 2024
P1, N=25, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Physicians should be mindful of the potential for TB recurrence following the use of ICIs, particularly in patients showing positive results from IGRA. Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Jul 2024
- | Tagrisso (osimertinib) / AstraZeneca, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy: Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (clinicaltrials.gov) - Jun 10, 2024
P1, N=24, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Jul 2024 Trial completion date: Apr 2025 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Apr 2025
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion: A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer (clinicaltrials.gov) - Jun 10, 2024
P=N/A, N=5, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2025 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Apr 2025 Active, not recruiting --> Completed
- | Enrollment change: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov) - Jun 9, 2024
P2, N=314, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=224 --> 314
- || Cabometyx (cabozantinib tablet) / Exelixis
Trial completion date, Trial primary completion date: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 9, 2024
P2, N=105, Active, not recruiting, Sponsor: Washington University School of Medicine
N=224 --> 314 Trial completion date: Jun 2029 --> Jun 2030 | Trial primary completion date: Jun 2024 --> Jun 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Checkpoint block: Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. (Pubmed Central) - Jun 8, 2024
Trial completion date: Jun 2029 --> Jun 2030 | Trial primary completion date: Jun 2024 --> Jun 2025 Fifty-five pretreatment and 12 paired on-treatment UC specimens were identified from patients treated with nivolumab with or without ipilimumab.
- ||| Biomarker, Clinical, Retrospective data, Review, Clinical Trial,Phase I, Journal, Adverse events, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review. (Pubmed Central) - Jun 7, 2024
The case observations highlight the plethora of uncertainties in diagnosis and treatment of ICI-associated nirAE, exemplify the heterogeneity of immune mechanisms involved, and suggest a role of B cells, which may be underdiagnosed. Intrathecal CXCL13 may serve as a biomarker of B cell involvement in nirAE, supported by intrathecal immunoglobulin synthesis, presence of plasma cells, and/or recruitment of cognate immune cells.
- |||| Trial completion, IO biomarker: Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (clinicaltrials.gov) - Jun 7, 2024
P2, N=251, Completed, Sponsor: Fondazione Melanoma Onlus
Intrathecal CXCL13 may serve as a biomarker of B cell involvement in nirAE, supported by intrathecal immunoglobulin synthesis, presence of plasma cells, and/or recruitment of cognate immune cells. Active, not recruiting --> Completed
- | Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data. (Pubmed Central) - Jun 6, 2024
In the poor-risk group, cabozantinib was more effective than axitinib. These findings provide valuable insights into the selection of second-line treatment options after nivolumab-ipilimumab treatment in patients with metastatic ccRCC.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition: Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes. (Pubmed Central) - Jun 6, 2024
Given that the prediction of new-onset ICI-T1DM is challenging, monitoring GAD antibody levels might be useful. However, further studies with large sample sizes and validation across different racial and ethnic populations are warranted.
- Yervoy (ipilimumab) / BMS
Phase classification: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Jun 6, 2024
P2, N=19, Completed, Sponsor: M.D. Anderson Cancer Center
However, further studies with large sample sizes and validation across different racial and ethnic populations are warranted. Phase classification: P2a --> P2
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical Trial,Phase II, Journal, Mismatch repair, Metastases: Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. (Pubmed Central) - Jun 5, 2024
P2
In patients with locally advanced dMMR colon cancer, neoadjuvant nivolumab plus ipilimumab had an acceptable safety profile and led to a pathological response in a high proportion of patients. (Funded by Bristol Myers Squibb; NICHE-2 ClinicalTrials.gov number, NCT03026140.).